DeVEnIR: Defining Vulvovaginal Candidiasis - Elements of Infection and Remedy

Launched by UNIVERSITY HOSPITAL, ANTWERP · Apr 29, 2024

Keywords

ClinConnect Summary

The DeVEnIR trial is studying vulvovaginal candidiasis (VVC), a common fungal infection that affects many women and can cause discomfort, pain, and emotional distress. The goal of this research is to understand the factors that contribute to VVC and to develop better ways to diagnose and treat it. The study will look at how the body's natural defenses, the balance of good and bad bacteria, and other factors play a role in this infection, especially for women who experience recurrent episodes.

To participate in the trial, women between the ages of 18 and 50 who are not pregnant and do not have any current vaginal symptoms are eligible. Participants can expect to provide samples and help researchers discover important information that could lead to new treatments. Additionally, the findings from this study aim to improve understanding and awareness of VVC, helping women feel more comfortable discussing their intimate health.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female
• • Age: 18-50
• • Premenopausal
• Exclusion Criteria:
• • Pregnancy
• • Self-reported vaginal complaints (e.g. redness, itching, pain, burning sensation, abnormal vaginal discharge) in the past 12 months (only for healthy group)
• • Use of antibiotics/antifungals in the month prior to sample collection (only for healthy group)